Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down9.700 -0.210 (-2.119%)

01/06/2020 14:34

BOCOM lifts Sino Biopharm (01177) to HK$14.08; "buy"

[ET Net News Agency, 1 June 2020] BOCOM Research lifted its target price for Sino
Biopharmaceutical (SBP)(01177) to HK$14.08 from HK$12.41 and maintained its "buy" rating.
The research house said SBP's 1Q adjusted attributable net profit of RMB834m missed
BOCOM's estimate by 4.3%. Growth was mainly dragged by hospital shutdown during the
pandemic, while rising R&D cost further weighed on profit.
Oncology portfolio, however, showed continued strong growth, which will be sustained by
Anlotinib's indication expansion, PD-1's launch in 2021, and Abiraterone & Gefitinib that
won the bid in PTQ (procurement with target quantity), BOCOM noted.
BOCOM revised its 2020-22 attributable net income by -6.7%/1.7%/6.9%. (KL)

Remark: Real time quote last updated: 07/08/2020 17:58
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.